Health Condition 1: H55-H57- Other disorders of eye and adnexa
Conditions
Interventions
Intervention1: NIL: NIL
Control Intervention1: NIL: NIL
Sponsors
Novartis Healthcare Pvt Ltd
Eligibility
Inclusion criteria
Inclusion criteria: Newly diagnosed nAMD patients Patients (male or female) aged >=50 years of age at Index date Patients diagnosed with nAMD in at least one eye Patients with VA/OCT assessments at both baseline, Month 12 and Month 24 Patients treated with intravitreal injection of anti-VEGF (received at least one anti-VEGF injection during the post-index follow-up period and at least 2 visits with OCT in between Months 0-12). Patients with minimum follow-up period of 24 months. (received at least one anti-VEGF injection and at least 1 visit with OCT in between Months 13-24)
Exclusion criteria
Exclusion criteria: Patients with dry AMD, geographic atrophy and other retinal diseases Patients who were part of any other trial/ study Patients undergoing additional ocular treatment along with Anti VEGF agents will be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Association between anatomical outcomes (presence /absence) at Month 12 and changes in functional outcome from baseline to Month 12 will be investigated for the following endpoints: Anatomical outcomes at Month 12 IRF (presence / absence) SRF (presence / absence) Sub-RPE (presence/ absence) Functional outcomes at baseline and Month 12 VA change from baseline (in ETDRS letters) Timepoint: 12 months | — |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate mean change in BCVA after the start of anti- VEGF therapy at Months 3, 6, 12, 18 and 24 as measured by ETDRS letters gained or lost.Timepoint: Months 3, 6, 12, 18 and 24 | — |
Countries
India
Contacts
Public ContactDr Maulik Bhavsar
Novartis Healthcare Pvt. Ltd.
Outcome results
None listed